5.09 0.43 (9.23%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 6.58 ![]() |
1-year : | 7.69 ![]() |
Resists | First : | 5.64 ![]() |
Second : | 6.58 ![]() |
Pivot price | 4.67 ![]() |
|||
Supports | First : | 4.93 ![]() |
Second : | 4.5 ![]() |
MAs | MA(5) : | 4.7 ![]() |
MA(20) : | 4.7 ![]() |
MA(100) : | 5.63 ![]() |
MA(250) : | 8.23 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 34.5 ![]() |
D(3) : | 23.4 ![]() |
RSI | RSI(14): 58.5 ![]() |
|||
52-week | High : | 23.17 | Low : | 3.8 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ SER ] has closed above the upper band by 21.6%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 68.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 5.65 - 5.67 | 5.67 - 5.69 |
Low: | 4.55 - 4.57 | 4.57 - 4.6 |
Close: | 5.05 - 5.09 | 5.09 - 5.12 |
Wed, 12 Feb 2025
Serina Therapeutics Appoints Dr. Jay Venkatesan to Board of Directors - Nasdaq
Wed, 12 Feb 2025
Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors - GlobeNewswire
Wed, 12 Feb 2025
Former Alpine Immune Sciences Founder Who Led $4.9B Exit Takes Board Seat at Serina - StockTitan
Mon, 03 Feb 2025
Serina secures additional $5 million for Parkinson's trial - MSN
Mon, 03 Feb 2025
Serina Therapeutics Secures Additional $5 Million Financing to Advance SER-252 into Phase 1 Trial for Advanced Parkinson's Disease - Nasdaq
Mon, 03 Feb 2025
Parkinson's Breakthrough: Serina Therapeutics Lands Premium-Priced $5M Investment to Advance Novel Treatment - StockTitan
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NYSE
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 0 (M) |
Shares Float | 9 (M) |
Held by Insiders | 2.94e+006 (%) |
Held by Institutions | 58.1 (%) |
Shares Short | 33 (K) |
Shares Short P.Month | 0 (K) |
EPS | -7.27e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 356.79 |
Profit Margin | -220.9 % |
Operating Margin | -7 % |
Return on Assets (ttm) | 580.3 % |
Return on Equity (ttm) | -45.3 % |
Qtrly Rev. Growth | 3.17e+006 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0.1 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -10 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0.01 |
Price to Sales | 0 |
Price to Cash Flow | -0 |
Dividend | 0 |
Forward Dividend | 27520 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |